EUVIMEDEUVIMED entdecken
Open Access

Mitigating aging and doxorubicin induced bone loss in mature mice via mechanobiology based treatments

Murtaza Wasi, Tiankuo Chu, Rosa M Guerra, Rory Kooker, Kenneth Maldonado, Xuehua Li, Chun-Yu Lin, Xin Song, Jinhu Xiong, Lidan You, Liyun Wang

Bone · 2024

DOI: 10.1016/j.bone.2024.117235 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bone, 2024. Verfasst von Murtaza Wasi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Mechanical Engineering, University of Delaware, Newark, DE, USA. Hauptthemen laut MEDLINE: Doxorubicin, Aging. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, National Institutes of Health, National Institute of General Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aging leads to a reduced anabolic response to mechanical stimuli and a loss of bone mass and structural integrity. Chemotherapy agents such as doxorubicin exacerbate the degeneration of aging skeleton and further subject older cancer patients to a higher fracture risk. To alleviate this clinical problem, we proposed and tested a novel mechanobiology-based therapy. Building upon prior findings that i) Yoda1, the Piezo1 agonist, promoted bone growth in young adult mice and suppressed bone resorption markers in aged mice, and ii) moderate tibial loading protected bone from breast cancer-induced osteolysis, we hypothesized that combined Yoda1 and moderate loading would improve the structural integrity of adult and aged skeletons in vivo and protect bones from deterioration after chemotherapy. We first examined the effects of 4-week Yoda1 (dose 5 mg/kg, 5 times/week) and moderate tibial loading (4.5 N peak load, 4 Hz, 300 cycles for 5 days/week), individually and combined, on mature mice (∼50 weeks of age). Combined Yoda1 and loading was found to mitigate age-associated cortical and trabecular bone loss better than individual interventions. As expected, the non-treated controls experienced an average drop of cortical polar moment of inertia (Ct.pMOI) by -4.3 % over four weeks and the bone deterioration occurred in the majority (64 %) of the samples. Relative to no treatment, loading alone, Yoda1 alone, and combined Yoda1 and loading increased Ct.pMOI by +7.3 %, +9.5 %, +12.0 % and increased the % of samples with positive Ct.pMOI changes by +32 %, +26 %, and +43 %, respectively, suggesting an additive protection of aging-related bone loss for the combined therapy. We further tested if the treatment efficacy was preserved in mature mice following two weeks (six injections) of doxorubicin at the dose of 2.5 or 5 mg/kg. As expected, doxorubicin increased osteocyte apoptosis, altered bone remodeling, and impaired bone structure. However, the effects induced by DOX were too severe to be rescued by Yoda1 and loading, alone or combined, although loading and Yoda1 individually, or combined, increased the number of mice showing positive responsiveness by 0 %, +15 %, and +29 % relative to no intervention after doxorubicin exposure. Overall, this study supported the potentials and challenges of the Yoda1-based strategy in mitigating the detrimental skeletal effects caused by aging and doxorubicin.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DoxorubicinAgingAnimalsFemaleMiceTibiaBone ResorptionMice, Inbred C57BLBiomechanical PhenomenaX-Ray MicrotomographyBiophysicsThiophenes

Stichwörter der Autor:innen

Bone remodelingChemotherapyMechanosensitive Piezo1Micro computed tomographyYoda1

Substanzen

DoxorubicinThiophenes

Autor:innen und Institutionen

  • Department of Mechanical Engineering, University of Delaware, Newark, DE, USA.
  • Department of Biomedical Engineering, University of Delaware, Newark, DE, USA.
  • Department of Biomedical Engineering, Kansas State University, Manhattan, KS, USA.
  • Department of Orthopaedic Surgery, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
  • Department of Mechanical and Industrial Engineering, Institute of Biomedical Engineering, University of Toronto, Toronto, Ontario, Canada.
  • Department of Mechanical Engineering, University of Delaware, Newark, DE, USA; Department of Biomedical Engineering, University of Delaware, Newark, DE, USA. Electronic address: lywang@udel.edu.

Förderung

  • NIGMS NIH HHS
  • National Institutes of Health
  • National Institute of General Medical Sciences

Zitieren

APA

Wasi, M., Chu, T., Guerra, R. M., Kooker, R., Maldonado, K., Li, X., Lin, C. Y., Song, X., Xiong, J., You, L., & Wang, L. (2024). Mitigating aging and doxorubicin induced bone loss in mature mice via mechanobiology based treatments. Bone. https://doi.org/10.1016/j.bone.2024.117235

Vancouver

Wasi M, Chu T, Guerra RM, Kooker R, Maldonado K, Li X, et al. Mitigating aging and doxorubicin induced bone loss in mature mice via mechanobiology based treatments. Bone. 2024. doi:10.1016/j.bone.2024.117235

BibTeX
@article{Wasi2024,
  author = {Wasi, Murtaza and Chu, Tiankuo and Guerra, Rosa M and Kooker, Rory and Maldonado, Kenneth and Li, Xuehua and Lin, Chun-Yu and Song, Xin and Xiong, Jinhu and You, Lidan and Wang, Liyun},
  title = {Mitigating aging and doxorubicin induced bone loss in mature mice via mechanobiology based treatments},
  journal = {Bone},
  year = {2024},
  doi = {10.1016/j.bone.2024.117235}
}
Kostenlos starten →